Ohio State Navbar

Directory

Samantha Jaglowski, MD


Staff photo

320 W 10th Ave
A354 Starling Loving Hall
Columbus, OH 43210

Phone: (614) 293-2268

Email: jaglowski.1@osu.edu

 

Current OSU Appointments

Assistant Professor-Clinical, Hematology

Physician, FGP-Hematology

 

Clinical Interest

Hematology

Biographical

The overarching theme of my career seems to be striving to make the most of opportunities and challenges presented. I earned my B.S. in zoology at the Ohio State University, graduating summa cum laude with honors in the Liberal Arts and Distinction in Zoology; my honors project evaluated the ability of ɣ-tocopheryl quinine to induce apoptosis in a HeLa cervical carcinoma cell line. When I was a third year medical student at Ohio State, I had the opportunity to rotate in the bone marrow transplant unit during my Internal Medicine clerkship. By the time I finished that rotation, I knew what I wanted to be when I grew up. Throughout physiology and pathophysiology, I found hematology interesting, and it was certainly on my short list, but it was not until I had an opportunity to interact with the patients and the team caring for them every day that I fell in love. I remained at Ohio State for internal medicine residency primarily because of Catherine Lucey and the program’s emphasis on excellent resident education. Early on in internship, I met John Byrd and became interested in chronic lymphocytic leukemia (CLL) and the immune defects inherent in the disease. I also gave birth to three daughters who taught me about priorities and time management.

I remained at Ohio State for a medical oncology fellowship with the intent of joining Dr. Byrd’s lab as a T32 fellow and with thoughts of ultimately specializing in transplant for CLL. Shortly after beginning my fellowship, I was diagnosed with a tumor invading my brainstem and learned all too well what it is like to be a cancer patient, given the choice between substantial morbidity with the possibility of a cure or preserved function with almost certain death, particularly given my age and the lack of chemotherapeutic options. My tumor was resected with curative intent, and I was fortunate to be allowed to return to work 6 months after my diagnosis, still undergoing extensive rehabilitation; my interest shifted toward late effects and survivorship research as well as early phase clinical trial design as a result. To that end, I enrolled in Ohio State’s College of Public Health, graduating with a Master’s in Public Health (MPH) in August 2012. As a fellow, I had the opportunity to design, write, and lead a prospective clinical trial combining ibrutinib, a novel BTK inhibitor, with ofatumumab, and this project led me being granted both an ASH Scholar Award and an ASCO Young Investigator Award.

Upon completing my medical oncology fellowship, I pursued an additional year of training in stem cell transplantation under the direction of Steve Devine, in part out of a desire to harness the immune system to be able to offer patients a potentially curative therapy in an area where chemotherapy so frequently fails. This cure often comes with a price, however, and my research focus is evaluating methods to mitigate or abrogate the potentially devastating effects of graft-versus-host disease (GVHD) and other complications of transplant, including novel targeted therapeutics. During this year, I devised and developed a clinical trial concept to study ibrutinib for the treatment of chronic GVHD and was accepted to the ASBMT Clinical Research Training Course to further develop this concept. This concept developed into a multi-center phase Ib/II study; we recently reported an overall response rate of 68% as a late-breaking abstract at the ASH 2016 Annual Meeting in a condition where the expected overall response rate is closer to 20-30%.

I remained on the faculty at The Ohio State University, becoming a tenure track Assistant Professor of Internal Medicine in the Division of Hematology in October 2011. I was fortunate to be awarded a position on Ohio State’s K12 for a phase I clinical trial evaluating milatuzumab as GVHD prophylaxis. I earned an ASBMT New Investigator Award with this study. Additionally, I have had the opportunity to serve as site principal investigator of two cellular therapy studies in lymphoma, the phase II Novartis CTL-019 study for DLBCL, and a phase I study of ACTR-modified T cells for CD20+ lymphomas. It is tremendously exciting to be on the cutting edge of this new therapeutic modality.

Over the past few years, I have been developing a Chronic Graft-Versus-Host Disease clinic, which has since evolved into a Long-Term Follow Up clinic, at Ohio State in order to streamline care for long-term survivors of allogeneic transplant, facilitating the recommended evaluations for these patients. We see patients at days 100, 180, 365, and then annually after transplant and ensure that common and less common but potentially devastating complications are not missed in the chaos of regular clinic time. This clinic will allow us to perform longitudinal studies of long-term survivors of stem cell transplant, including collecting and banking biologic specimens. Ohio State has joined the Chronic GVHD Consortium, led by Dr. Stephanie Lee at the Fred Hutchinson Cancer Research Center, and I am serving as our local principal investigator. A large part of this consortium is an R01 study evaluating the natural history of patients with cGVHD and validating response metrics. In addition to having the opportunity to participate in Consortium studies, this gives us access to a wonderful group of collaborators should our initial studies prove interesting, and through this consortium, we have been able to participate in a randomized phase II study comparing rituximab to imatinib for sclerotic cGVHD and will shortly be opening a phase II study evaluating carfilzomib in the same patient population.

Because research in late effects of transplant is heavily clinically focused, I have become more interested in process improvement and quality improvement, and have been struck by the development of silos within the program. In an attempt to improve communication across groups, I have developed a monthly BMT Program Workgroup, where representatives from each of the groups come together, learn about what each of us does on a daily basis, and brings ideas for improvement and collaboration. I was recently named the clinical director of the blood and marrow transplant program and thus have responsibility for daily operations of the clinic. In this capacity, I work closely with nurses, nurse practitioners, the cell therapy lab, BMT coordinators and others to ensure that our patients receive the best care possible. To help with my new position, I have enrolled in the Masters of Business Operational Excellence program at the Fisher College of Business. This program focuses on process improvement, quality, management, and leadership skills, all of which will be invaluable to me in my new position. In the coming year, I will take advantage of the opportunity to participate in the Transplant Committee of the Alliance for Clinical Trials in Oncology and in the BMT Clinical Trials Network, presented by Dr. Devine’s leadership positions in both of those organizations. This will foster networking and will present opportunities for collaboration outside of my institution. As I move forward, I am very excited to use everything I have learned in my time at Ohio State to help our BMT program move from great to exceptional.

Academic Advising

2013 Brad Haverkos, The Ohio State University. Graduated 2015.
2016 Polina Shindiapina, The Ohio State University. Graduated 0.
2016 Nathan Denlinger, The Ohio State University. Graduated 0.
2014 , The Ohio State University.
2014 - 2015 Marcello Rotta, The Ohio State University. Graduated 2015.
 

Licenses

2009 - present Board Certification: American Board of Internal Medicine
2010 - present Medical License: State Medical Board of Ohio
2011 - present Board Certification: American Board of Internal Medicine
 

Clinical Services

11/01/2011 Outpatient Hematopoietic Cell Transplant Clinic (James Cancer Hospital, Internal Medicine, Division of Hematology)
12/01/2011 Inpatient Bone Marrow Transplant (BMT) Service (James Cancer Hospital, Internal Medicine, Division of Hematology)
12/01/2012 Inpatient Hematology 4 Service (James Cancer Hospital)
08/01/2014 Outpatient Long-Term Follow-Up Clinic (James Cancer Hospital)
01/01/2011 - 06/01/2013 Inpatient Hematology 1 (HEM 1) Service (James Cancer Hospital, Internal Medicine, Division of Hematology)
04/01/2011 - 06/01/2013 Inpatient Hematology 3 (HEM 3) Service (James Cancer Hospital, Internal Medicine/Division of Hematology)

Conferences

Jaglowski SM, Lin TL, Elder P, Scholl D, Byrd JC, Devine SM, Andritsos LA.. "Barriers to Reduced-Intensity Conditioning (RIC) Transplant in Patients with Chronic Lymphocytic Leukemia." In BLOOD. (November 2009). 559-560.

Jaglowski SM, Byrd JC, Jones JA. "In-Hospital Mortality and Trends Associated with Splenectomy in Patients with Immune-Mediated Thrombocytopenia (ITP).." In BLOOD. (November 2009). Abstract #1374-.

Jaglowski SM, Flynn JM, Jones JA, Lin TS, Fischer B, Scholl D, Elder P, Devine SM, Grever MR, Byrd JC, Andritsos LA.. "Flavopiridol Is An Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant." In BLOOD. (November 2010). 987-988.

Herman SEM, Gordon AL, Mahoney E, Jaglowski SM, Blum KA, Buggy J, Hamdy A, Byrd JC, Johnson AJ. "The Kinase Inhibitor, PCI-32765, Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals." In BLOOD. (November 2010). 596-596.

Jaglowski SM, Heerema N, Elder P, Scholl D, Hamadani M, Byrd JC, Devine SM, Andritsos LA. "Complex Karyotype Predicts Poor Response to Salvage Therapy and Ineligibility for Reduced Intensity Conditioning Transplantation in CLL." In Biology of Blood and Marrow Transplantation. (February 2010). Abstract #335-.

Jaglowski SM, Heerema NA, Elder P, Byrd JC, Devine SM, Andritsos LA. "Increasing Genetic Complexity Predicts for Inferior Outcomes Following Reduced-Intensity Conditioning Allogeneic Transplant for Chronic Lymphocytic Leukemia." In BLOOD. (November 2011). 1335-1335.

Jaglowski SM, Hofmeister CC, Elder P, Penza S, Efebera YA, Benson DM, Devine SM, Andritsos LA. "The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma." In BLOOD. (November 2012). Abstract #4286-.

Hamadani M, Craig M, Remick S, Gibson L, Petros W, Abraham J, Cumpston A, Bunner P, Basu S, Tse W, Hennelly C, Vasu S, Klisovic RB, Blum W, Jaglowski SM, Benson DM, Andritsos LA, Penza S, Hofmeister CC, Geyer S, Devine SM, Efebera YA. "Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT)." In BLOOD. (November 2012). abstract #1942-.

Jaglowski SM, Vasu S, Geyer S, Bingman A, Elder P, Yu J, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Andritsos LA, Lozanski G. "Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease." In BLOOD. (November 2012). Abstract #1949-.

Vasu S, Jaglowski SM, Geyer S, Bingman A, Elder P, Yu J, Andritsos LA, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Lozanski G. "Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)." In BLOOD. (November 2012). Abstract 4192-.

Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, Maddocks KJ, Blum KA, Grever MR, Geyer S, Woyach JA, Johnson AJ, Heerema NA, Molnar E, Stefanos M, Devlin S, Navarro T, James D, Lowe A, Hedrick E, Byrd JC.. "A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.." In JOURNAL OF CLINICAL ONCOLOGY. (May 2012). Abstract #6508-.

Yu J, He S, Wu L, Mao H, Vasu S, Jaglowski SM, Peng Y, Alvarez-Breckenridge C, Yuan S, Wei M, Zhang J, Hughes TL, Ghoshal K, Devine SM, Caligiuri MA.. "Micrornas Promote Activation and Maturation of Natural Killer Cells Through Toll-Like Receptor Signaling.." In BLOOD. (November 2012). Abstract #2160-.

Dubovsky JA, Beckwith KA, Woyach JA, Jaglowski SM, Hessler J, Chang BY, Larkin K, Stefanovski MR, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman A, Furman RR, Sharman J, Mishra A, Caligiuri MA, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. "Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells." In BLOOD. (November 2012). Abstract #775-.

Blum KA, Christian B, Flynn JM, Jaglowski SM, Jones JA, Maddocks KJ, Byrd JC. "A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)." In BLOOD. (November 2012). Abstract #1643-.

Efebera Y, Geyer S, Bingman A, Kitzler R, Elder P, Hennelly C, Andritsos LA, Jaglowski SM, Blum W, Klisovic RB, Penza S, Vasu S, Hofmeister CC, Benson DM, Devine SM, Lozanski G. "Impact of Atorvastatin On Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2013). S202-S202.

Salem S, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos LA, Klisovic RB, Vasu S, Blum W, Devine SM, Jaglowski SM, Efebera YA. "Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity (RIC) Allogeneic Hematopoeitic Stem Cell Transplant (HSCT)." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2013). S304-S305.

Stephens DM, Ruppert AS, Jones J, Woyach J, Maddocks K, Jaglowski S, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC. "Changing the treatment paradigm for previously treated chronic lymphocytic leukemia patients with del(17p) karyotype." In BLOOD. (November 2013). Abstract #2872-.

Stephens D, Ruppert AS, Wierda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam CS, O’Brien S, Keating MJ, Muthusamy R, Abruzzo LV, Heerema NA, Byrd JC. "Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients." In BLOOD. (November 2013). Abstract #4128-.

Pandit A, Wei L, Elder P, Falk W, Sell M, Hofmeister CC, Benson DM, Penza S, Andritsos LA, Klisovic R, Vasu S, Blum W, Devine SM, JaglowskiSM, Efebera YA. "Autologous Hematopoietic Stem Cell Transplant (aHSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL amyloidosis)." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2013). S186-S186.

El-Jawahri A, Pidala J, Chai X, Wood WA, Khera N, Arora M, Jaglowski SM, Lee SJ, Chen Y. "Do older patients with moderate-severe chronic graft-versus-host disease differ from younger patients?." In BLOOD. (November 2013). Abstract #725-.

Haverkos BM, Cortright K, Andritsos LA, Blum W, Klisovic RB, Vasu S, Goldenberg DM, Wegener WA, Devine SM, Jaglowski SM. A. "A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies." In BLOOD. (December 2014). Abstr #1168-.

Efebera YA, Geyer S, Bingman A, Kitzler R, Elder P, Andritsos LA, Jaglowski SM, Vasu S, Blum W, Klisovis RB, Penza S, Coombes K, Hofmeister CC, Benson D, Devine SM, Lozanski G. "Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)." In BLOOD. (December 2014). Abstr #1166-.

Efebera YA, Geyer S, Bingman A, Elder P, Kitzler R, Coombes K, Hennelly C, Cortright K, Andritsos LA, Jaglowski SM, Vasu S, Blum W, Klisovic RB, Penza S, Hofmeister CC, Benson DM, Lozanski G, Devine SM. "Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT)." In BLOOD. (December 2014). Abstract #3929-.

Dubovsky,JA; Flynn,R; Du,J; Harrington,BK; Zhong,Y; Yang,C; Towns,W; Lehman,A; Johnson,A; Devine,S; Jaglowski,S; Serody,JS; Murphy,WJ; Munn,DH; Luznik,L; Hill,G; MacDonald,KP; Maillard,I; Koreth,J; Cutler,C; Soiffer,RJ; Antin,JH; Ritz,J; Panoskaltsis-Mortari,A; Byrd,JC; Blazar,BR. "Ibrutinib can reverse established chronic graft-versus-host disease, which is dependent upon IL-2 inducible T-cell kinase (ITK) and Bruton's tyrosine kinase (BTK)-driven lymphocyte activation." In CANCER RESEARCH. (October 2014). Abstract 2591-.

Christian,B; Wei,L; Sexton,J; Jaglowski,SM; Devine,SM; Fehniger,TA; Wagner-Johnston,N; Bartlett,NL; Blum,KA. "A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)." In BLOOD. (December 2014). #3099-.

Maddocks K, Ruppert AS, Lozanski G, Lozanski A, Heerema N, Heerema NA, Abruzzo L, Gordon A, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. "Disease Progression on Ibrutinib Therapy is Uncommon and is Associated with the Acquisition of Resistance Mutations: A Single Center Experience of 267 Patients." In HAEMATOLOGICA. (June 2014). 521-521.

Yang KS, Dubovsky JA, Chappell DL, Harrington BK, Jaglowski S, Woyach JA, Johnson AJ, Muthusamy N, Byrd JC. "Immune modulating agent ibrutinib blocks T-helper 17 activation and release of IL-17A while preserving T-regulatory cell function." In CANCER RESEARCH. (October 2014). .-.

Vasu S, Bingman A, Geyer S, Elder P, Kitzler R, Bradbury H, O’Donnell L, Blum W, Jaglowski SM, Andritsos LA, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Lozanski G, Devine SM. "Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation." In BLOOD. (December 2014). Abstr #2494-.

Rogers KA, Woyach JA, Andritsos LA, Awan F, Blum KA, Flynn JM, Jaglowski S, Lozanski G, Maddocks KJ, Byrd JC, Jones JA. "Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib." In BLOOD. (December 2014). Abstr #1997-.

Maddocks KJ, Cohen JB, Christian B, Flynn JM, Jaglowski SM, Blum KA. "A Phase II Study of MLN8237 (Alisertib) Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (NHL)." In BLOOD. (December 2014). Abstr #3082-.

Guinn D, Ruppert AS, Maddocks KJ, Jaglowski SM, Gordon AL, Lin TS, Larson RA, Marcucci G, Hertlein EK, Woyach JA, Johnson AJ, Byrd JC. "Mir-155 Expression Is Associated with Chemoimmunotherapy Outcome and Is Modulated By Bruton's Tyrosine Kinase Inhibition with Ibrutinib." In BLOOD. (December 2014). Abstr #3297-.

Coutre,S; O'Brien,S; Byrd,JC; Hillmen,P; Brown,JR; Dyer,MJS; Mato,AR; Miklos,DB; Keating,M; Zhou,C; Fardis,M; Styles,L; Jaglowski,S. "Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant." In BLOOD. (December 2014). Abstract 4697-.

Christian B, Wei L, Sexton J, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston N, Bartlett NL, Blum KA. "A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin’s Lymphoma." In BLOOD. (December 2014). Abstract 3099-.

El-Jawahri A, Pidala J, Chai X, Wood WA, Khera N, Arora M, Jaglowski S, Lee SJ, Chen Y. "The Impact of Age on Quality of Life, Functional Status, and Overall Survival in Patients with Moderate-Severe Chronic Graft-versus-Host Disease." In Biology of Blood and Marrow Transplantation. (February 2014). S65-S65.

McBride A, Geyer S, Jaglowski S, Devine SM, Andritsos LA.. "Plerixafor Mobilization in MM Patients and Impact on CD34 Cell Collection and Transplant Outcomes." In Biology of Blood and Marrow Transplantation. (February 2014). S293-S293.

Haverkos BM, Geyer S, McBride A, Penza S, Devine SM, Andritsos LA, Jaglowski S. "Mobilization for Autologous Stem Cell Transplantation in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma: A Single Institution Experience." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2014). S111-S112.

Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Geyer SM, Heerema NA, Lozanski G, Stefanos M, Hall N, Nagar V, Munneke B, West J, Neuenburg J, James DF, Johnson AJ, Byrd JC.. "A Phase 1b/2 Study Evaluating Activity and Tolerability of the BTK Inhibitor Ibrutinib in Combination with Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Related Diseases.." In Journal of Clinical Oncology. (May 2014). 32:52 Abstract #7009-.

Woyach JA, Ruppert AS, Lozanski G, Lozanski A, Heerema NA, Zhao W, Abruzzo L, Gordon A, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Maddocks KJ. "Association of Disease Progression on Ibrutinib Therapy with the Acquisition of Resistance Mutations: A Single-Center Experience of 267 Patients." In Journal of Clinical Oncology. (May 2014). Abstract #7010-.

Issa,H; Ruppert,AS; Elder,P; Hofmeister,C; Benson,DM; Penza,S; Andritsos,LA; Klisovic,RB; Vasu,S; Blum,W; Jaglowski,SM; Devine,SM; Efebera,YA. "Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)." In BLOOD. (December 2015). .-.

Haverkos B, Cortright K, Andritsos LA, Blum W, Klisovic R, Vasu S, Goldenberg DM, Wegener W, Devine SM, Jaglowski S. "A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2015). S331-S332.

Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Palmer J, Chen GL, Khera N, Mayer S, Jagasia MH, Wood WA, Martin PJ, Inamoto Y, Miklos DB, Lee SJ, Flowers MED. "A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant." In BIOL BLOOD MARROW TRANSPLANT. (February 2015). S32-.

Efebera YA, Geyer S, Andritsos L, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmiester CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O'Donnell L, Daneault B, Bradbury H, Zhang J, Chen X, Garman S, Ranganathan P, Yu X, Hofstetter J, Yu J, Garzon R, Scrape SR, Devine SM, Lozanski G. "Impact of Atorvastatin on Immune Reconstitution and cytokines of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)." In BONE MARROW TRANSPLANTATION. (March 2015). S398-S398.

Miklos DB, Coutre S, O’Brien S, Byrd JC, Hillmen P, Brown JR, Dyer M, Mato AR, Keating M, Zhou C, Fardis M, Styles L, Jaglowski S.. "Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant." In BIOL BLOOD MARROW TRANSPLANT. (February 2015). S82-.

Efebera YA, Geyer S, Bingman A, Elder P, Kitzler R, Coombes K, Hennelly C, Cortright K, Andritsos LA, Jaglowski SM, Vasu S, Blum W, Klisovic RB, Penza S, Hofmeister CC, Benson DM, Lozanski G, Devine SM. "Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT)." In BONE MARROW TRANSPLANTATION. (March 2015). S397-S398.

Miklos,DB; Arora,M; Cutler,CS; Nakamura,R; Juretic,M; Li,Y; Styles,LA; James,DF; Jaglowski,SM. "A multicenter open-label phase 1b/2 study of ibrutinib in steroid dependent or refractory chronic graft versus host disease (cGVHD)." In JOURNAL OF CLINICAL ONCOLOGY. (May 2015). #7024-.

Jaglowski,SM; Jones,JA; Flynn,JM; Andritsos,LA; Maddocks,KJ; Woyach,JA; Blum,KA; Grever,MR; Geyer,SM; Heerema,NA; Lozanski,G; Stefanos,M; Hall,N; Nagar,V; Munneke,B; West,J; Neuenburg,JK; James,DF; Johnson,AJ; Byrd,JC. "Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)." In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. (June 2015). S206-S207.

Rosko AE, Hofmeister CC, Efebera YA Benson DM, Sborov D, Jaglowski S, Devine S, Wildes TM, Gillahan J, Jones D, Huang Y, Burd CE. "Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients." In BLOOD. (December 2015). .-.

O'Brien, S, Jaglowski S, Byrd JC, Bannerji R, Blum K, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James D, Chu AD, Coutre S. "Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL." In BLOOD. (December 2015). .-.

Rotta M, Wei L, Kitzler R, Bradbury H, Bingman A, Vasu S, Jaglowski S, Blum W. "Significant Impact of Mobilization Strategy on the Cellular Composition of Donor Allografts." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (March 2016). S351-S352.

Singer S, Efebera YA, Zhao Q, Abounader D, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, Jaglowski S, William BM, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Majhail N, Devine SM, Dean R. "A Two-Center Retrospective Comparison of BEAM vs BUCYVP16 Conditioning Prior to Autologous Hematopoietic Stem Cell Transplantation In Patients With Hodgkin's Lymphoma." In HAEMATOLOGICA. (June 2016). 625-625.

Issa H, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos LA, Klisovic R, Jaglowski SM, Efebera YA. "Antithymocyte Globulin (ATG) 4.5 Vs. 6.0 Mg/Kg in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (March 2016). S316-S317.

Miklos D, Cutler C, Arora M, Walker E, Jagasia M, Nakamura R, Blazar B, Juretic B, Li Y, Dubovsky J, James D, Styles L, Jaglowski S.. "Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid-Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)." In BONE MARROW TRANSPLANTATION. (March 2016). S176-S177.

Singer S, Efebera YA, Zhao Q, Abounader D, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, Jaglowski S, William BM, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Majhail N, Devine SM, Dean R. "A Two-Center Retrospective Comparison of BEAM vs BUCYVP16 Conditioning Prior to Autologous Hematopoietic Stem Cell Transplantation in Non-Hodgkin's Lymphoma." In HAEMATOLOGICA. (June 2016). 625-626.

Miklos D, Cutler C, rora M, Waller E, Jagasia M, Nakamura R, Blazar B, Juretic M, Li Y, Dubovsky J, James D, Styles L, Jaglowski S. "Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid-Dependent/Refractory Chronic Graft Versis Host Disease (cGVHD)." In Bone Marrow Transplant. (May 2016). #124-.

Jaglowski S, Waller EK, Kindwall-Keller TL, McCarty JM, Dugan M, Yellin M, Davis T, Devine SM. "Preliminary Safety and Efficacy Data Using CDX-301 (Flt3 ligand) as a Sole Agent to Mobilize Hematopoietic Cells Prior to HLA-Matched Sibling Donor Transplantation." In Biol Blood Marrow Transplant. (February 2016). S324-.

 

Degrees

2000 B.S., The Ohio State University

2004 M.D., The Ohio State University

2012 M.Public Hlth., The Ohio State University

2017 None Indicated, The Ohio State University

 

Editorial Activities

2010 - present Leukemia
2012 - present Expert Review of Hematology
2012 - present Blood
2012 - present Expert Reviews in Anticancer Therapy
2012 Biology of Blood and Marrow Transplantation
2013 - present Personalized Medicine
2013 - present Haematologica
2013 - present Future Medicine
2013 Drugs of the Future
2014 - present New England Journal of Medicine
2014 Current Opinon in Hematology
2016 - present Acta Hematologica
 

Honors

2000 Phi Beta Kappa. Phi Beta Kappa.
2001 Letter of Commendation in Medical Humanities. The Ohio State University.
2001 Arthritis Foundation Grant. Arthritis Foundation.
2002 Letter of Commendation in Pediatrics. The Ohio State University.
2002 Honors in Psychiatry. The Ohio State University.
2003 Letter of Commendation in Internal Medicine. The Ohio State University.
2003 Honors in Medical Education.
2004 Honors in Gynecology. The Ohio State University.
2004 Honors in Pain/Palliative Care. The Ohio State University.
2010 Outstanding Clinical Care by a Fellow. The Ohio State University College of Medicine.
2011 American Society of Hematology Scholar Award. American Society of Hematology.
2011 JCO Young Investigator Award. American Society of Clinical Oncology.
2012 - present ASBMT Clinical Research Training Course. American Society of Blood and Marrow Transplantation.
2012 - 2014 K12 Scholar. National Institutes of Health.
2013 - present NIH Loan Repayment Award. National Institute of Health.
2013 - 2015 ASBMT New Investigator Award. American Society of Blood and Marrow Transplantation.
2015 - 2016 NIH Loan Repayment Award. National Institutes of Health.
 

Journal Articles

Jaglowski SM; Linden E; Termuhlen AM; Flynn JM. "Lymphoma in adolescents and young adults.." Seminars In Oncology. Vol. 36, no. 5. (October 2009.): 381-.

Jaglowski SM. "Lovenox hurts.." Annals Of Internal Medicine. Vol. 151, no. 8. (October 2009.): 585-.

Jaglowski SM. "Lovenox hurts.." Annals of Internal Medicine. Vol. 151, no. 8. (October 2009.): 585-586.

Jaglowski SM, Linden E, Termuhlen AM, Flynn JM. "Lymphoma in Adolescents and Young Adults." Seminars in Oncology. Vol. 36, no. 5. (October 2009.): 381-418.

Jaglowski SM; Byrd JC. "Rituximab in chronic lymphocytic leukemia.." Seminars In Hematology. Vol. 47, no. 2. (April 2010.): 156-.

Jaglowski SM, Alinari L, Lapalombella R, Muthusamy R, Byrd JC. "The Clinical Application of Monoclonal Antibodies in CLL." Blood. (November 2010.): 3705-3714.

Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. "The clinical application of monoclonal antibodies in chronic lymphocytic leukemia." Blood. Vol. 116, no. 19. (November 2010.): 3705-3714.

Jaglowski SM, Byrd JC. "Rituximab in Chronic Lymphocytic Leukemia." Seminars in Hematology. Vol. 47, no. 2. (April 2010.): 156-169.

Jaglowski S, Jones JA. "Choosing first-line therapy for chronic lymphocytic leukemia." Expert Review of Anti Cancer Therapy. Vol. 11, no. 9. (September 2011.): 1379-1390.

Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC. "Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765." Blood. Vol. 117, no. 23. (June 2011.): 6287-6296.

Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC.. "Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765." BLOOD. Vol. 117, no. 23. (November 2011.): 6287-6296.

Jaglowski SM, Ruppert AS, Heerema NA, Bingman A, Flynn JM, Grever MR, Jones Ja, Elder P, Devine SM, Byrd JC, Andritsos LA. "Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.." British journal of haematology. Vol. 159, no. 1. (October 2012.): 82-87.

Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, Maddocks KJ, Blum KA, Grever MR, Geyer SM, Woyach JA, Johnson AJ, Heerema NA, Molnar E, Stefanos M, Devlin S, Navarro T, James DF, Lowe AM, Hedrick E, Byrd JC. "A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.." JOURNAL OF CLINICAL ONCOLOGY. Vol. 30, no. 15. (May 2012.): .-.

Jaglowski SM, Byrd JC. "Novel Therapies and Their Integration into Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia." Biology of Blood and Marrow Transplantation. Vol. 18, no. 1. (January 2012.): S132-S138.

Blum KA, Christian BA, Flynn JM, Jaglowski SM, Jones JA, Maddocks KJ, Byrd JC. "A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)." BLOOD. Vol. 120, no. 21. (November 2012.): .-.

Jaglowski SM, Hofmeister CC, Elder P, Penza S, Efebera YA, Benson DM, Devine SM, Andritsos LA,. "The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma." BLOOD. Vol. 120, no. 21. (November 2012.): 1323-1329.

Dubovsky,Jason,A; Beckwith,Kyle,A; Natarajan,Gayathri; Woyach,Jennifer,A; Jaglowski,Samantha; Zhong,Yiming; Hessler,Joshua,D; Liu,Ta-Ming; Chang,Betty,Y; Larkin,Karilyn,M; Stefanovski,Matthew,R; Chappell,Danielle,L; Frissora,Frank,W; Smith,Lisa,L; Smucker,Kelly,A; Flynn,Joseph,M; Jones,Jeffrey,A; Andritsos,Leslie,A; Maddocks,Kami; Lehman,Amy,M; Furman,Richard; Sharman,Jeff; Mishra,Anjali; Caligiuri,Michael,A; Satoskar,Abhay,R; Buggy,Joseph,J; Muthusamy,Natarajan; Johnson,Amy,J; Byrd,John,C. "Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes." BLOOD. Vol. 122, no. 15. (October 2013.): 2539-2549.

El Jawahri A, Pidala J, Inamoto Y, Chai X, Khera N, Wood WA, Cutler C, Arora M, Carpenter PA, Palmer J, Flowers M, Weisdorf D, Pavletic S, Jaglowski S, Jagasia M, Lee SJ, Chen YB. "Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease." Biology of Blood Marrow Transplantation. Vol. 20, no. 9. (September 2014.): 1341-1348.

Haverkos B, McBride A, O’Donnell L, Scholl D, Whittaker B, Vasu S, Penza S, Andritsos L, Devine S, Jaglowski S.. "An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor." Bone Marrow Transplant. Vol. 49, no. 8. (September 2014.): 1052-1055.

Hofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM, Blum K, Porcu P, Flynn J, Penza S, Benson DM, Andritsos LA, Devine SM. "A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma." Leuk Lymphoma. Vol. [Epub ahead of print], (September 2014.): .-.

Jaglowski,S,M; Ruppert,A,S; Hofmeister,C,C; Elder,P; Blum,W; Klisovic,R; Vasu,S; Penza,S; Efebera,Y,A; Benson,D,M; Devine,S,M; Andritsos,L,A. "The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma." BONE MARROW TRANSPLANTATION. Vol. 49, no. 10. (October 2014.): 1323-1329.

Jaglowski SM. "Transplant for CLL: still an option?." Blood. Vol. 124, no. 26. (December 2014.): 3835-6.

Dubovsky,Jason,A; Flynn,Ryan; Du,Jing; Harrington,Bonnie,K; Zhong,Yiming; Kaffenberger,Benjamin; Yang,Carrie; Towns,William,H; Lehman,Amy; Johnson,Amy,J; Muthusamy,Natarajan; Devine,Steven,M; Jaglowski,Samantha; Serody,Jonathan,S; Murphy,William,J; Munn,David,H; Luznik,Leo; Hill,Geoffrey,R; Wong,Henry,K; MacDonald,Kelli,KP; Maillard,Ivan; Koreth,John; Elias,Laurence; Cutler,Corey; Soiffer,Robert,J; Antin,Joseph,H; Ritz,Jerome; Panoskaltsis-Mortari,Angela; Byrd,John,C; Blazar,Bruce,R. "Ibrutinib treatment ameliorates murine chronic graft-versus-host disease." JOURNAL OF CLINICAL INVESTIGATION. Vol. 124, no. 11. (November 2014.): 4867-4876.

Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera YA. "Lower dose of antithymocyte globulin (ATG) does not increase graft-versus-host disease (GVHD) in patients undergoing reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplant (allo-HSCT)." Leuk Lymphoma. Vol. [Epub ahead of print], (August 2014.): .-.

Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM, Jaglowski S, Penza S, Andritsos LA, Devine SM. "Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study." Support Care Cancer. Vol. [Epub ahead of print], (May 2014.): .-.

Jaglowski SM, Devine SM. "Graft-versus-host disease: why have we not made more progress?." CURRENT OPINION IN HEMATOLOGY. Vol. 21, no. 2. (March 2014.): 141-147.

Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM, Devine SM, Andritsos LA.. "The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma." Bone Marrow Transplant. Vol. [Epub ahead of print], (July 2014.): .-.

Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, LiDH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC. "Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib." New England Journal of Medicine. Vol. 370, no. 24. (June 2014.): 2286-94.

El Jawahri A, Pidala J, Inamoto Y, Chai X, Khera N, Wood WA, Cutler C, Arora M, Carpenter PA, Palmer J, Flowers M, Weisdorf D, Pavletic S, Jaglowski S, Jagasia M, Lee SJ, Chen YB. "Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease." Biology of Blood Marrow Transplantation. Vol. 20, no. 9. (September 2014.): 1341-1348.

Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks KJ, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC. "Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center." LEUKEMIA. Vol. 28, no. 6. (June 2014.): 1365-1368.

Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM, Devine SM, Andritsos LA. "The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma." New England Journal of Medicine. Vol. 370, no. 24. (June 2014.): 2286-94.

Jaglowski,SM; Jones,JA; Nagar,V; Flynn,JM; Andritsos,LA; Maddocks,KJ; Woyach,JA; Blum,KA; Grever,MR; Smucker,K; Ruppert,AS; Heerema,NA; Lozanski,G; Stefanos,M; Munneke,B; West,J; Neuenburg,JK; James,DF; Hall,N; Johson,AJ; Byrd,JC. "Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study." BLOOD. Vol. 126, no. 7. (August 2015.): 842-850.

Maddocks,Kami,J; Ruppert,Amy,S; Lozanski,Gerard; Heerema,Nyla,A; Zhao,Weiqiang; Abruzzo,Lynne; Lozanski,Arletta; Davis,Melanie; Gordon,Amber; Smith,Lisa,L; Mantel,Rose; Jones,Jeffrey,A; Flynn,Joseph,M; Jaglowski,Samantha,M; Andritsos,Leslie,A; Awan,Farrukh; Blum,Kristie,A; Grever,Michael,R; Johnson,Amy,J; Byrd,John,C; Woyach,Jennifer,A. "Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.." JAMA oncology. Vol. 1, no. 1. (April 2015.): 80-87.

Guinn,D; Ruppert,A,S; Maddocks,K; Jaglowski,S; Gordon,A; Lin,T,S; Larson,R; Marcucci,G; Hertlein,E; Woyach,J; Johnson,A,J; Byrd,J,C. "miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib." LEUKEMIA. Vol. 29, no. 5. (May 2015.): 1210-1213.

Jaglowski,Samantha,M; Jones,Jeffrey,A; Flynn,Joseph,M; Andritsos,Leslie,A; Maddocks,Kami,J; Woyach,Jennifer,A; Blum,Kristie,A; Greyer,Michael,R; Geyer,Susan,Michelle; Heerema,Nyla,A; Lozanski,Gerard; Stefanos,Mona; Hall,Nathan; Nagar,Veena; Munneke,Brian; West,Jamie-Sue; Neuenburg,Jutta,K; James,Danelle,F; Johnson,Amy,J; Byrd,John,C. "Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. Vol. 15, (June 2015.): S206-S207.

Amin E, Phillips G, Elder P, Jaglowski S, Devine S, Wood K. "Health related quality of life in patients that develop bronchiolitis obliterans syndrome following allogeneic stem cell transplantation." Bone Marrow Transplant. Vol. 50, no. 2. (February 2015.): 289-95.

Liu,Ta-Ming; Woyach,Jennifer,A; Zhong,Yiming; Lozanski,Arletta; Lozanski,Gerard; Dong,Shuai; Strattan,Ethan; Lehman,Amy; Zhang,Xiaoli; Jones,Jeffrey,A; Flynn,Joseph; Andritsos,Leslie,A; Maddocks,Kami; Jaglowski,Samantha,M; Blum,Kristie,A; Byrd,John,C; Dubovsky,Jason,A; Johnson,Amy,J. "Hypermorphic mutation of phospholipase C, gamma 2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation." BLOOD. Vol. 126, no. 1. (July 2015.): 61-68.

Stephens,Deborah,M; Ruppert,Amy,S; Weirda,William,G; Jones,Jeffrey,A; Woyach,Jennifer,A; Maddocks,Kami; Jaglowski,Samantha,M; Andritsos,Leslie,A; Flynn,Joseph,M; Grever,Michael,R; Lozanski,Gerard; Tam,Constantine; O'Brien,Susan; Keating,Michael,J; Muthusamy,Natarajan; Abruzzo,Lynne,V; Heerema,Nyla,A; Byrd,John,C. "Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients." AMERICAN JOURNAL OF HEMATOLOGY. Vol. 90, no. 11. (November 2015.): 967-969.

Flynn J, Jones J, Jonhson AJ, Andritsos L, Maddocks K, Jaglowski S, Hesler J, Grever MR< Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. "Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia." Leukemia. Vol. 29, no. 7. (July 2015.): 1524-9.

Maddocks,Kami; Christian,Beth; Jaglowski,Samantha; Flynn,Joseph; Jones,Jeffery,A; Porcu,Pierluigi; Wei,Lai; Jenkins,Cynthia; Lozanski,Gerard; Byrd,John,C; Blum,Kristie,A. "A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma." BLOOD. Vol. 125, no. 2. (January 2015.): 242-248.

Bachanova,Veronika; Burns,Linda,J; Ahn,Kwang,Woo; Laport,Ginna,G; Akpek,Goerguen; Kharfan-Dabaja,Mohamed,A; Nishihori,Taiga; Agura,Edward; Armand,Philippe; Jaglowski,Samantha,M; Cairo,Mitchell,S; Cashen,Amanda,F; Cohen,Jonathon,B; D'Souza,Anita; Freytes,Cesar,O; Gale,Robert,Peter; Ganguly,Siddhartha; Ghosh,Nilanjan; Holmberg,Leona,A; Inwards,David,J; Kanate,Abraham,S; Lazarus,Hillard,M; Malone,Adriana,K; Munker,Reinhold; Mussetti,Alberto; Norkin,Maxim; Prestidge,Tim,D; Rowe,Jacob,M; Satwani,Prakash; Siddiqi,Tanya; Stiff,Patrick,J; William,Basem,M; Wirk,Baldeep; Maloney,David,G; Smith,Sonali,M; Sureda,Anna,M; Carreras,Jeanette; Hamadani,Mehdi. "Impact of Pretransplantation F-18-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 21, no. 9. (September 2015.): 1605-1611.

Vasu,Sumithira; Geyer,Susan; Bingman,Anissa; Auletta,Jeffery,J; Jaglowski,Samantha; Elder,Pat; O'Donnell,Lynn,C; Bradbury,Hillary; Kitzler,Rhonda; Andritsos,Leslie; Blum,William; Klisovic,Rebecca; Penza,Sam; Efebera,Yvonne; Hofmeister,Craig; Benson,Don,M; Muthusamy,Natarajan; Lozanski,Gerard; Devine,Steven,M. "Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease (vol 22, pg 658, 2016)." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 22, no. 7. (July 2016.): 1341-1341.

Roddy,Julianna,VF; Haverkos,Bradley,M; McBride,Ali; Leininger,Kathryn,M; Jaglowski,Samantha; Penza,Sam; Klisovic,Rebecca; Blum,William; Vasu,Sumithira; Hofmeister,Craig,C; Benson,Don,M; Andritsos,Leslie,A; Devine,Steven,M; Efebera,Yvonne,A. "Tocilizumab for steroid refractory acute graft-versus-host disease." LEUKEMIA & LYMPHOMA. Vol. 57, no. 1. (January 2016.): 81-85.

Rogers,K,A; Ruppert,A,S; Bingman,A; Andritsos,L,A; Awan,F,T; Blum,K,A; Flynn,J,M; Jaglowski,S,M; Lozanski,G; Maddocks,K,J; Byrd,J,C; Woyach,J,A; Jones,J,A. "Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia." LEUKEMIA. Vol. 30, no. 2. (February 2016.): 346-350.

Kaffenberger,B,H; Zhang,E; Duncan,J,R; Jaglowski,S; Klisovic,R,B; Devine,S,M; Wong,H,K; Gru,A,A. "Endothelial chimerism in chronic sclerotic-type chronic graft-versus-host disease (GVHD) and GVHD-associated angiomatosis.." British journal of dermatology. Vol. 175, no. 4. (October 2016.): 782-784.

Vela,Cory,M; McBride,Ali; Jaglowski,Samantha,M; Andritsos,Leslie,A. "Ibrutinib for treatment of chronic lymphocytic leukemia." AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY. Vol. 73, no. 6. (March 2016.): 367-375.

Efebera,Yvonne,A; Geyer,Susan; Andritsos,Leslie; Vasu,Sumithira; Jaglowski,Samantha; Bingman,Anissa; Blum,William; Klisovic,Rebecca; Hofmeister,Craig,C; Benson,Don,M; Penza,Sam; Elder,Patrick; Cortright,Katie; Kitzler,Rhonda; Coombes,Kevin; O'Donnell,Lynn; Daneault,Beth; Bradbury,Hillary; Zhang,Jianying; Chen,Xilin; Garman,Sabrina; Ranganathan,Parvathi; Yu,Xueyan; Hofstetter,Jessica; Yu,Jianhua; Garzon,Ramiro; Scrape,Scott,R; Lozanski,Gerard; Devine,Steven,M. "Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT)." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 22, no. 1. (January 2016.): 71-79.

Arai,Sally; Pidala,Joseph; Pusic,Iskra; Chai,Xiaoyu; Jaglowski,Samantha; Khera,Nandita; Palmer,Jeanne; Chen,George,L; Jagasia,Madan,H; Mayer,Sebastian,A; Wood,William,A; Green,Michael; Hyun,Teresa,S; Inamoto,Yoshihiro; Storer,Barry,E; Miklos,David,B; Shulman,Howard,M; Martin,Paul,J; Sarantopoulos,Stefanie; Lee,Stephanie,J; Flowers,Mary,ED. "A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation." CLINICAL CANCER RESEARCH. Vol. 22, no. 2. (January 2016.): 319-327.

Vasu,Sumithira; Geyer,Susan; Bingman,Anissa; Auletta,Jeffery,J; Jaglowski,Samantha; Elder,Pat; Donnell,Lynn,O; Bradbury,Hillary; Kitzler,Rhonda; Andritsos,Leslie; Blum,William; Klisovic,Rebecca; Penza,Sam; Efebera,Yvonne; Hofmeister,Craig; Benson,Don,M; Muthusamy,Natarajan; Lozanski,Gerard; Devine,Steven,M. "Granulocyte Colony-Stimulating Factor Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 22, no. 4. (April 2016.): 658-668.

Fenske,Timothy,S; Ahn,Kwang,W; Graff,Tara,M; DiGilio,Alyssa; Bashir,Qaiser; Kamble,Rammurti,T; Ayala,Ernesto; Bacher,Ulrike; Brammer,Jonathan,E; Cairo,Mitchell; Chen,Andy; Chen,Yi-Bin; Chhabra,Saurabh; D'Souza,Anita; Farooq,Umar; Freytes,Cesar; Ganguly,Siddhartha; Hertzberg,Mark; Inwards,David; Jaglowski,Samantha; Kharfan-Dabaja,Mohamed,A; Lazarus,Hillard,M; Nathan,Sunita; Pawarode,Attaphol; Perales,Miguel-Angel; Reddy,Nishitha; Seo,Sachiko; Sureda,Anna; Smith,Sonali,M; Hamadani,Mehdi. "Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.." British journal of haematology. Vol. 174, no. 2. (July 2016.): 235-248.

Vasu,S; Wu,H; Satoskar,A; Puto,M; RODDY,J; Blum,W; Klisovic,R; Andritsos,L; Hofmeister,C; Benson,D,M; Efebera,Y; Jaglowski,S; Penza,S; Cohen,D; Devine,S; Cataland,S. "Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy.." Bone marrow transplantation. Vol. 51, no. 9. (September 2016.): 1241-1244.

Ghosh,Nilanjan; Karmali,Reem; Rocha,Vanderson; Ahn,Kwang,Woo; DiGilio,Alyssa; Hari,Parameswaran,N; Bachanova,Veronika; Bacher,Ulrike; Dahi,Parastoo; de Lima,Marcos; D'Souza,Anita; Fenske,Timothy,S; Ganguly,Siddhartha; Kharfan-Dabaja,Mohamed,A; Prestidge,Tim,D; Savani,Bipin,N; Smith,Sonali,M; Sureda,Anna,M; Waller,Edmund,K; Jaglowski,Samantha; Herrera,Alex,F; Armand,Philippe; Salit,Rachel,B; Wagner-Johnston,Nina,D; Fuchs,Ephraim; Bolaños-Meade,Javier; Hamadani,Mehdi. "Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.." Journal of clinical oncology. Vol. 34, no. 26. (September 2016.): 3141-3149.

Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, Miklos DB. "Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT." Blood. -.

Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Axim H, Lehmann L, Yu L, Bitan M, Cairo MS, Quayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashni S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS. "GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes." Bone Marrow Transplant. -.

 

Presentations

"Barriers to Reduced-Intensity Conditioning (RIC) Transplant in Patients with Chronic Lymphocytic Leukemia." Presented at American Society of Hematology Annual Meeting 2009 (ASH), Orlando, FL, US|USA. (December 2009)

"In-Hospital Mortality and Trends Associated with Splenectomy in Patients with Immune-Mediated Thrombocytopenia (ITP)." Presented at American Society of Hematology Annual Meeting 2009 (ASH), Orlando, FL, US|USA. (December 2009)

"Lovenox Hurts." Presented at Annals of Internal Medicine, . (October 2009)

"Lovenox Hurts." Presented at Annals of Internal Medicine Podcast, . (December 2009)

"Flavopiridol is an Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant." Presented at American Society of Hematology Annual Meeting 2010 (ASH), Orlando, FL, US|USA. (December 2010)

"Complex Karyotype Predicts Poor Response to Salvage Therapy and Ineligibility for Reduced Intensity Conditioning Complex Karyotype Predicts Poor Response to Salvage Therapy and Ineligibility for Reduced Intensity Conditioning Transplantation in CLL." Presented at American Society for Blood and Marrow Transplantation Annual Meeting 2010 (ASBMT), Orlando, FL, US|USA. (February 2010)

"Salvage Regimens with Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era: the CORAL Study." Presented at Bone Marrow Transplant Journal Club, Columbus. (May 2011)

"Project Cancer Education." Presented at Project Cancer Education, . (October 2011)

"Leukemia, Myelodysplasia and Pediatric Oncology." Presented at 4th Annual World Cancer Congress, Dalian, CN|CHN. (May 2011)

"Clinical benefit of response in chronic graft-versus-host disease." Presented at Bone Marrow Transplant Journal Club, . (August 2012)

"The hematopoietic stem cell transplant comorbidity index (HCT-CI) can predict for readmission following autologous stem cell transplant for lymphoma and multiple myeloma." Presented at American Society of Hematology Annual Meeting (ASH), Atlanta, GA, US|USA. (December 2012)

"A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases." Presented at American Society of Clinical Oncology Annual Meeting (ASCO), Chicago, IL, US|USA. (June 2012)

"Immune reconstitution at days 30 and 100 following allogeneic stem cell transplant and association with subsequent development of chronic graft-versus-host disease." Presented at American Society of Hematology Annual Meeting (ASH), Atlanta, GA, US|USA. (December 2012)

"Clinical Oncology and Medical Practice." Presented at 5th Annual World Cancer Congress, Beijing, CN|CHN. (May 2012)

"Medical Research on Hematology and Oncology and Endocrine System Tumors." Presented at 6th Annual World Cancer Congress, Hilton Xi'an, CN|CHN. (May 2013)

"A Phase 1b/2 Study Evaluating Activity and Tolerability of the BTK Inhibitor Ibrutinib in Combination with Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Related Diseases." Presented at American Society of Clinical Oncology Annual Meeting 2014 (ASCO), Chicago, IL, US|USA. (June 2014)

"Leukemia and Lymphoma of Stream 2: Best Clinical Practice Forum; Best Clinical Practice on Cancer Treatment." Presented at 7th Annual World Cancer Congress, Nanjing, CN|CHN. (May 2014)

"Preliminary safety and efficacy data using CDX-301 (Flt3 ligand) as a sole agent to mibiliza hematopoietic cells prior to HLA-matched sibling donor transpalntation." Presented at American Society of Blood and Marrow Transplantation Annual Meeting 2016, Honolulu, HI, US|USA. (February 2016)

 

Unpublished Works

Haverkos B, Huang Y, Elder P, O'Donnell L, Scholl D, Whittaker B, Vasu S, Panza S, Andritsos L, Devine S, Jaglowski S. A singel center's experience using four different front-line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation. September 2016.